Human myeloid inhibitory C-lectin: a highly specific and stab e acute myeloid leukemia marker

被引：7
作者：
Eissa, Deena Samir [1 ]
Kandeel, Eman Zaghloul [2 ]
Ghareeb, Mohamed [3 ]
机构：
[1] Ain Shams Univ, Dept Clin Pathol, Fac Med, Cairo, Egypt
[2] Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Cairo, Egypt
[3] Cairo Univ, Natl Canc Inst, Dept Med Oncol, Cairo, Egypt
来源：
HEMATOLOGICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
acute myeloid leukemia; human myeloid inhibitory C-lectin; minimal residual disease; relapse; FLOW-CYTOMETRY; STEM-CELL; GENE-COMPLEX; DIAGNOSIS; EXPRESSION; RELAPSE; IMMUNOPHENOTYPES; MOLECULE-1; PHENOTYPES; NEOPLASMS;
D O I：
10.1002/hon.2352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of acute myeloid leukemia (AML) is poor because of relapses occurring on conventional chemotherapy. The distinction between leukemic and normal stem cells relies on the expression of antigen combinations defining leukemia-associated immunophenotypes (LAIPs), which are absent or extremely infrequent in normal bone marrow. However. LAIPs are very different from patient to patient and are not necessarily stable over the course of the disease. Accordingly, we addressed the applicability of human myeloid inhibitory C-lectin (hMICL) by flow cytometry as a specific leukemic myeloid stem cell marker for the diagnosis of AML in CD34(+) and CD34(-) cases and evaluated the stability of hMICL during the course of the disease. hMICL expression was assessed in 78 bone marrow aspirate specimens obtained from AML patients at diagnosis (n = 40), complete remission (CR) (n = 28), and relapse (n = 10). AML patients at diagnosis were compared to 20 newly diagnosed acute lymphoblastic leukemia (ALL) patients and 20 healthy controls. hMICL was reevaluated in CR and relapse specimens. hMICL was expressed in 100% AML patients at diagnosis (mean +/- standard deviation [SD], 60.3 +/- 19.9%). both CD34(+) and CD34(-), but not in ALL (mean +/- SD, 3.3 +/- 1.9%) or healthy controls (mean +/- SD, 3.4 +/- 2.6%) (P < .001). hMICL median fluorescence intensity ratio was higher in AML (mean +/- SD, 15.9 +/- 11.7) compared to ALL (mean +/- SD, 4.5 +/- 1.4) and healthy controls (mean +/- SD, 4.4 +/- 1.6) (P < .001). hMICL was expressed in all studied AML morphologic subtypes. Preserved stable expression of hMICL was found in CR and relapse specimens with no antigen loss. hMICL is a robust pan-AML-associated antigen with excellent diagnostic impact, extreme specificity to AML blasts, and stability throughout the course of the disease. hMICL could be incorporated into the routine flow cytometry setting within the initial diagnostic work-up and follow-up of AML.
引用
收藏
页码：814 / 820
页数：7
相关论文
共 28 条
[1]   The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia [J].
Al-Mawali, A. ;
To, L. B. ;
Gillis, D. ;
Hissaria, P. ;
Mundy, J. ;
Lewis, I. .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2009, 31 (01) :61-68
[2]   Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry [J].
Al-Mawali, Adhra ;
Gillis, David ;
Hissaria, Pravin ;
Lewis, Ian .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (06) :934-945
[3]   Age and acute myeloid leukemia [J].
Appelbaum, FR ;
Gundacker, H ;
Head, DR ;
Slovak, ML ;
Willman, CL ;
Godwin, JE ;
Anderson, JE ;
Petersdorf, SH .
BLOOD, 2006, 107 (09) :3481-3485
[4]   Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders [J].
Bain, BJ ;
Barnett, D ;
Linch, D ;
Matutes, E ;
Reilly, JT .
CLINICAL AND LABORATORY HAEMATOLOGY, 2002, 24 (01) :1-13
[5]   C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia [J].
Bakker, ABH ;
van den Oudenrijn, S ;
Bakker, AQ ;
Feller, N ;
van Meijer, M ;
Bia, JA ;
Jongeneelen, MAC ;
Visser, TJ ;
Bijl, N ;
Geuijen, CAW ;
Marissen, WE ;
Radosevic, K ;
Throsby, M ;
Schuurhuis, GJ ;
Ossenkoppele, GJ ;
de Kruif, J ;
Goudsmit, J ;
Kiuisbeek, AM .
CANCER RESEARCH, 2004, 64 (22) :8443-8450
[6]   Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].
Cheson, BD ;
Bennett, JM ;
Kopecky, KJ ;
Büchner, T ;
Willman, CL ;
Estey, EH ;
Schiffer, CA ;
Döhner, H ;
Tallman, MS ;
Lister, TA ;
LoCocco, F ;
Willemze, R ;
Biondi, A ;
Hiddemann, W ;
Larson, RA ;
Löwenberg, B ;
Sanz, MA ;
Head, DR ;
Ohno, R ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649
[7]   Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].
Fernandez, Hugo F. ;
Sun, Zhuoxin ;
Yao, Xiaopan ;
Litzow, Mark R. ;
Luger, Selina M. ;
Paietta, Elisabeth M. ;
Racevskis, Janis ;
Dewald, Gordon W. ;
Ketterling, Rhett P. ;
Bennett, John M. ;
Rowe, Jacob M. ;
Lazarus, Hillard M. ;
Tallman, Martin S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259
[8]   Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring [J].
Langebrake, C ;
Brinkmann, I ;
Teigler-Schlegel, A ;
Creutzig, U ;
Griesinger, F ;
Puhhnann, U ;
Reinhardt, D .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2005, 63B (01) :1-9
[9]   Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up [J].
Larsen, Hanne O. ;
Roug, Anne S. ;
Just, Tom ;
Brown, Gordon D. ;
Hokland, Peter .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (01) :3-8
[10]   Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse [J].
Li, Xin ;
Du, Wen ;
Liu, Wei ;
Li, Xiaoqing ;
Li, Hongrui ;
Huang, Shi-Ang .
APMIS, 2010, 118 (05) :353-359
123